A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Kappaproct as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients.

Trial Profile

A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Kappaproct as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Cobitolimod (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms COLLECT
  • Sponsors InDex Pharmaceuticals
  • Most Recent Events

    • 19 Oct 2016 Results of post-hoc analysis presented at the 24th United European Gastroenterology Week.
    • 19 Oct 2016 Post hoc analysis results presented at the 24th United European Gastroenterology Week
    • 18 Oct 2016 According to an InDex Pharmaceuticals media release, result from the COLLECT study was presented at the United European Gastroenterology Week (UEGW).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top